UniQure’s gene therapy AMT-061 looking promising mid trial
UniQure’s experimental gene therapy has shown sustained Factor IX activity in a Phase II study assessing its potential to treat haemophilia B.
Read More
Tag: UniQure
UniQure’s haemophilia B therapy picks up PRIME status
uniQure’s investigational gene therapy for patients with the blood clotting disorder haemophilia B has been awarded PRIME status by European regulators, potentially placing the treatment on a faster path to approval.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
